News https://www.iddo.org/news.rss en First ever international conference on Medicine Quality and Public Health starts soon in Oxford https://www.iddo.org/news/first-ever-international-conference-medicine-quality-and-public-health-starts-soon-oxford <div class="iddo-page-wrapper row full-width"> <div class="col-sm-12 full-width-gutter content-introduction-area"> <div class="row"> <div class="col-xs-12 col-sm-8 col-md-8"> <div class="field field--name-node-title field--type-ds field--label-hidden field--item"><h1> First ever international conference on Medicine Quality and Public Health starts soon in Oxford </h1> </div> <div class="news-type-and-date"> <div class="field field--name-node-post-date field--type-ds field--label-hidden field--item">21 Sep 2018</div> </div> <div class="field field--name-field-introduction field--type-text-long field--label-hidden field--item"><p><span><span><span>The <span><a href="https://www.iddo.org/">Infectious Diseases Data Observatory (IDDO)</a></span>, together with many partners including the <span><a href="http://www.usp.org/">United States Pharmacopeia (USP)</a></span>, the <span><a href="https://www.conceptfoundation.org/">Concept Foundation</a></span>, the <span><a href="http://www.tropmedres.ac/home">Mahidol Oxford Tropical Medicine Research Unit (MORU)</a></span> and the Wellcome Trust will host the first Medicine Quality and Public Health conference at Keble College, Oxford, 23-28 September 2018.  </span></span></span></p></div> </div> <div class="col-xs-12 col-sm-4 col-md-4"> <div class="field field--name-field-image field--type-image field--label-hidden field--item"> <img src="/sites/default/files/styles/standard_image_crop/public/news/DieoeNJXcAAOX1D.jpg?itok=GKXlfXnW" width="600" height="397" alt="MQPH 2018 conference" title="MQPH 2018 conference" typeof="foaf:Image" class="img-responsive" /> </div> </div> </div> </div> <div class="col-sm-12 full-width-gutter content-bottom"><div class="row"> <div class="col-xs-12 col-sm-8 col-md-9"> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p><span><span><span>Close to 200 experts from around 50 countries will attend the conference to <a href="/news/experts-seek-consensus-tackling-poor-quality-medicines"><span>discuss strategies and exchange ideas for tackling the proliferation of poor quality medicines and medical products</span></a>. This important, but often neglected public health problem, threatens the lives of millions both in low-and-middle-income and high-income countries. </span></span></span></p> <p><span><span><span>The conference aims to strengthen partnerships across different sectors from academia, public health, pharmacy and chemistry to law and ethics. A consensus statement, coordinated by <span><a href="https://www.iddo.org/mq/iddo-staff/professor-paul-newton">Professor Paul Newton</a></span>, based at the <span><a href="http://www.tropmedres.ac/lomwru-laos">Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit (LOMWRU)</a></span> will be discussed at the end of the conference. </span></span></span></p> <p><span><span><span>Professor Paul Newton explains, ‘<em>The statement will outline the key opportunities and suggested ‘next steps’ to tackle medicine quality challenges. The conference provides us with an excellent opportunity to foster closer collaboration and international coordination on matters relating to medicine quality</em>.’</span></span></span></p> <p><span><span><span>Dr Suzanne Hill, Director of the Essential Medicines and Health Products Department of the World Health Organization (WHO) will be joined by opening speaker Professor Louise Richardson, Vice-Chancellor of the University of Oxford, Agnes Sitta Kijo, Acting Director General of the Tanzanian Food and Drugs Authority (TFDA), Professor Mojisola Christianah Adeyeye, Director General of the Nigerian National Agency for Food &amp; Drug Administration and Control (NFDA) and <span><a href="https://www.iddo.org/professor-sir-nicholas-white-frs">Professor Sir Nicholas White</a></span>, Chairman of the Wellcome Trust Mahidol Oxford Tropical Medicine Research Unit.</span></span></span></p> <p><span><span><span>Dr Raffaella Ravinetto, senior researcher at the Institute of Tropical Medicine in Antwerp and scientific advisor at QUAMED, will chair the first conference session on preventing, detecting and responding to poor quality medicines. Michael Deats, the World Health Organization’s (WHO) group lead for Substandard and Falsified Medical Products, will provide an overview of poor quality medicine, including the causes, consequences and WHO’s role in addressing the challenges. In the afternoon, Professor Sir Nicholas White will chair a session reviewing the latest evidence on the contribution of poor quality medicines to increasing <span><a href="https://www.iddo.org/research-themes/antimicrobial-resistance">antimicrobial resistance (AMR)</a></span>. </span></span></span></p> <p><span><span><span>There will be a number of short talks throughout the conference on a range of medicine quality topics including: challenges and detection of falsified medicines in developing countries delivered by Dr Richard Jähnke, project manager of the Global Pharma Health Fund on the morning of Tuesday 25 September.</span></span></span></p> <p><span><span><span>On Tuesday 25 September, delegates will learn about the economics and policy influencing medicine quality at a session chaired by Fiona Theunissen, programme manager at the Concept Foundation in Geneva.</span></span></span></p> <p><span><span><span>IDDO will lead a number of sessions at the conference including a discussion on the accuracy and cost-effectiveness of current technologies to screen for poor quality medicines on the morning of Tuesday 25 September. <span><a href="https://www.iddo.org/malaria/iddo-staff/professor-philippe-guerin">Professor Philippe Guérin</a></span>, Director of IDDO, will co-chair with <span><a href="https://www.iddo.org/mq/iddo-staff/dr-celine-caillet">Dr Céline Caillet</a></span>, IDDO’s Medicine Quality Research Scientist. The session will share findings of an IDDO-MORU systematic review, <a href="https://gh.bmj.com/content/3/4/e000725" target="_blank"><span>published in the BMJ Global Health journal</span></a> that evaluated screening technologies for poor quality medicines. In the afternoon IDDO will host a session optimising survey techniques and data sharing to help tackle poor quality, substandard and falsified medicines.</span></span></span></p> <p><span><span><span>On Wednesday 26 September, delegates will attend talks on the ethics, corruption and public trust related to medicine quality. Experts from the pharmaceutical industry, legal, and financial sectors will lead discussions on Thursday 27 September – sharing perspectives on how to strengthen medicine regulation in different economic and political contexts. Dr Souly Phanouvong, Director of Global Public Health Asia at USP, will chair a session on the pre-qualification of medical products on the Thursday afternoon.</span></span></span></p> <p><span><span><span>The conference will conclude, Friday 28 September with talks from Marie Lamy, Director of Access and Policy at APLMA, discussing the problem of falsified and substandard antimalarial medicines in the Greater Mekong Subregion and policy-making in Cambodia, Laos and Thailand. Marie Lamy will be joined by Dr Katherine Bond, Vice President of International Public Policy and Regulatory Affairs at USP, who will talk about USP’s <span><a href="https://medswecantrust.org/">‘Medicines We Can Trust’ campaign</a></span>, promoting safe, quality medicine for all. IDDO alongside partners’ the <span><a href="http://www.wwarn.org/">Worldwide Antimalarial Resistance Network (WWARN)</a></span> are supporters and members of the campaign. </span></span></span></p> <p><span><span><span><span><a href="https://twitter.com/IDDOnews">Follow <strong>@IDDOnews</strong></a></span> to read the conference highlights and tweet using <strong>#MQPH2018 </strong>and #MedsWeCanTrust</span></span></span></p> <p><span><span><span>For delegate information please <span><a href="https://www.tropicalmedicine.ox.ac.uk/medicinequality2018/generalinformation/">visit this page</a></span> and full programme details can be found in the <span><a href="https://www.tropicalmedicine.ox.ac.uk/medicinequality2018/wp-content/uploads/2018/09/MQPH-2018-Conference-Brochure.pdf">conference brochure</a></span>.</span></span></span></p> <p><span><span><span>For media enquiries please e-mail Andrea Stewart: <span>andrea.stewart@iddo.org</span>.</span></span></span></p> <p><span><span><span>If you’re not attending the conference, but would like to learn more about our work on Medicine Quality, please visit <span><a href="mailto:our%20Medicine%20Quality%20page">our Medicine Quality page</a></span> or <span><a href="mailto:e-mail%20info@iddo.org">e-mail info@iddo.org</a></span>.</span></span></span></p></div> </div> <div class="col-xs-12 col-sm-4 col-md-3"> </div> </div></div> <div class="col-sm-12 content-paragraphs"> </div> </div> Fri, 21 Sep 2018 14:51:42 +0000 Bradley 363 at https://www.iddo.org 9th EDCTP Forum starts this week https://www.iddo.org/news/9th-edctp-forum-starts-week <div class="iddo-page-wrapper row full-width"> <div class="col-sm-12 full-width-gutter content-introduction-area"> <div class="row"> <div class="col-xs-12 col-sm-8 col-md-8"> <div class="field field--name-node-title field--type-ds field--label-hidden field--item"><h1> 9th EDCTP Forum starts this week </h1> </div> <div class="news-type-and-date"> <div class="field field--name-node-post-date field--type-ds field--label-hidden field--item">18 Sep 2018</div> </div> <div class="field field--name-field-introduction field--type-text-long field--label-hidden field--item"><p>We are delighted to attend the 9th EDCTP Forum in Lisbon, Portugal this week.</p></div> </div> <div class="col-xs-12 col-sm-4 col-md-4"> <div class="field field--name-field-image field--type-image field--label-hidden field--item"> <img src="/sites/default/files/styles/standard_image_crop/public/news/IMG-20180918-WA0003.jpg?itok=AIfCoY7E" width="600" height="450" alt="Sama Cherif presenting at ‘Data-sharing for global research good’ symposium" title="Sama Cherif presenting at ‘Data-sharing for global research good’ symposium" typeof="foaf:Image" class="img-responsive" /> </div> </div> </div> </div> <div class="col-sm-12 full-width-gutter content-bottom"><div class="row"> <div class="col-xs-12 col-sm-8 col-md-9"> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>Our first Scientific Symposium, in partnership is on <strong>Tuesday 18th September at 10.30am</strong> on the theme <em>‘Data-sharing for global research good’</em>.</p> <p><a href="/vl/iddo-staff/michael-ochieng-otieno">Michael Ochieng Otieno</a>, EDCTP-TDR Fellow, will present his experience of developing a <a href="/research-themes/visceral-leishmaniasis">data-sharing platform for visceral leishmaniasis (VL)</a> from DNDi.</p> <p><a href="https://www.iddo.org/malaria/iddo-staff/dr-paul-sondo">Paul Sondo</a> will discuss how the WorldWide Antimalarial Resistance Network (WWARN) has generated reliable research evidence by analysing antimalarial drug resistance research data on the <a href="https://www.iddo.org/research-themes/malaria">malaria platform</a>.</p> <p>Sama Cherif will discuss establishing equitable governance for the launch of the <a href="/research-themes/ebola">Ebola data platform</a>.  </p> <p>Elizabeth Allen, Senior Scientist at WWARN's Southern Africa hub, will present on WWARN's Clinical Trials Toolkit.</p> <p>This symposium will be held in Auditorium 2.</p> <p><strong>On Thursday 20th September at 14:30</strong>, <a href="/malaria/iddo-staff/professor-philippe-guerin">Philippe Guérin</a> will join <a href="/ebola/iddo-staff/laura-merson">Laura Merson</a>, <a href="/professor-oumar-gaye">Oumar Gaye</a> and colleagues from <a href="https://tghn.org/" target="_blank">The Global Health Network (TGHN) </a>to present a <em>‘Data-sharing workshop’</em> that will include a presentation of IDDO’s experience of gathering and analysing data for emerging infections and infectious diseases including malaria, Ebola, VL and schistosomiasis.</p> <p>Philippe Guérin and Laura Merson will focus on the research, management and ethical implications of sharing data globally.</p> <p>Oumar Gaye will present his experience of leading research collaborations in our <a href="http://www.wwarn.org/about-us/regional-centres/west-africa-regional-centre" target="_blank">West Africa Regional Centre</a>, primarily focussed on malaria drug resistance data-sharing under the auspices of WWARN.</p> <p>This workshop will be held in Auditorium 3.</p> <p>Sama Cherif will present a poster on '<strong><em>Establishing an equitable governance framework for an Ebola data-sharing platform' poster 8522.</em></strong></p> <p>We’ll be sharing news from the conference via Twitter – <a href="https://twitter.com/IDDOnews" target="_blank">follow @IDDOnews</a> to read the conference highlights.</p> <p><a href="http://www.edctpforum2018.org/" target="_blank">Visit the EDCTP Forum website</a>.</p> <p>If you’re not going to EDCTP, we hope to see you at ASTMH 2018 in New Orleans, USA. Let us know if you’re attending as we’d like to connect. Email <a href="mailto:info@iddo.org">info@iddo.org</a></p></div> </div> <div class="col-xs-12 col-sm-4 col-md-3"> </div> </div></div> <div class="col-sm-12 content-paragraphs"> </div> </div> Tue, 18 Sep 2018 09:27:22 +0000 Bradley 362 at https://www.iddo.org Study details high hidden economic costs of antibiotic consumption https://www.iddo.org/news/study-details-high-hidden-economic-costs-antibiotic-consumption <div class="iddo-page-wrapper row full-width"> <div class="col-sm-12 full-width-gutter content-introduction-area"> <div class="row"> <div class="col-xs-12 col-sm-8 col-md-8"> <div class="field field--name-node-title field--type-ds field--label-hidden field--item"><h1> Study details high hidden economic costs of antibiotic consumption </h1> </div> <div class="news-type-and-date"> <div class="field field--name-node-post-date field--type-ds field--label-hidden field--item">22 Aug 2018</div> </div> <div class="field field--name-field-introduction field--type-text-long field--label-hidden field--item"><p>Bangkok / Oxford, 22 August 2018 – The economic costs of antimicrobial resistance (AMR) for every course of antibiotics are considerable, and much higher than their purchase cost, say researchers.</p></div> </div> <div class="col-xs-12 col-sm-4 col-md-4"> <div class="field field--name-field-image field--type-image field--label-hidden field--item"> <img src="/sites/default/files/styles/standard_image_crop/public/news/C0142715_lo.jpg?itok=fcnpM-HW" width="600" height="400" alt="The economic costs of antimicrobial resistance (AMR) are higher than the sales price of most popular antibiotics, according to a recent MORU/IDDO study. Curbing the unnecessary use of antibiotics is key to dealing with the AMR issue head on, particularly in SE Asia, which has the highest rates of AMR and a big, informal medicine dispensing sector that aggravates the AMR problem. ©2018 MORU/Wellcome." title="The economic costs of antimicrobial resistance (AMR) are higher than the sales price of most popular antibiotics, according to a recent MORU/IDDO study. Curbing the unnecessary use of antibiotics is key to dealing with the AMR issue head on, particularly in SE Asia, which has the highest rates of AMR and a big, informal medicine dispensing sector that aggravates the AMR problem. ©2018 MORU/Wellcome." typeof="foaf:Image" class="img-responsive" /> </div> </div> </div> </div> <div class="col-sm-12 full-width-gutter content-bottom"><div class="row"> <div class="col-xs-12 col-sm-8 col-md-9"> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p><span><span><span><span><span>In a </span></span><span><u><span><a href="http://bit.ly/2OZ1MiL">landmark study</a></span></u></span><span><span>, a team of researchers led by the Mahidol Oxford Research Centre (MORU) and the </span></span><span><u><span><a href="http://www.iddo.org">Infectious Diseases Data Observatory (IDDO)</a></span></u></span><span><span> used data from the USA and Thailand to link the consumption of antibiotics with the direct and indirect costs of treating patients for five drug-resistant bacterial infections.</span></span></span></span></span></p> <p><span><span><span><span><span>In a first, the experts looked at the consequences of antibiotic treatment failure –  higher death rates, lost earnings, more expensive diagnostics, costs to care providers and health systems – to calculate in USD the cost of antimicrobial resistance (AMR) for five types of antibiotic drugs widely used in the USA, a high-income country (HIC),  and in Thailand, a lower-middle income country (LMIC).</span></span></span></span></span></p> <p><span><span><span><span><span>These estimates will help us to better understand the true costs of AMR associated with antibiotic consumption. They provide policy makers and health carers with data they can use to decide on how best to deploy their limited resources to fight drug-resistant infections,” says first author, </span></span>Poojan Shrestha, researcher at the <span><u><a href="http://www.iddo.org">IDDO</a></u></span>.</span></span></span></p> <p><span><span><span>The study found that in the US, a full course of amoxicillin, which costs under USD10, had an additional AMR cost of US$18.60. In Thailand, a full course of widely used amoxicillin/clavulanic acid, which can be purchased for under USD2 over the counter in most pharmacies, had an estimated AMR cost of USD10.40. Multiplying each drug’s AMR costs by the number of treatment doses would allow health authorities to make better, more informed treatment decisions, the authors say.</span></span></span></p> <p><span><span><span>These figures will allow us to make more evidence-based health care decisions – and consider alternatives such as low-cost rapid diagnostic tests to confirm bacterial infection, a measure which could help reduce antibiotic consumption and slow the spread of drug-resistant infections,” said Prof. <span><u><a href="mailto:http://www.tropmedres.ac/researchers/researcher/yoel-lubell">Yoel Lubell</a></u></span>, lead author and Senior Health Economist at <span><u><a href="http://www.tropmedres.ac/home">MORU</a></u></span>.</span></span></span></p> <p><span><span><span>Each year, an estimated 700,000 people around the world die of drug resistant infections, with one report estimating that this will rise to 10 million people a year unless proactive solutions are found to slow the rise of AMR infections.</span></span></span></p> <p><span><span><span>This study is an important first attempt to produce a menu of estimates for the costs of AMR and provides a useful benchmark by comparing two locations and contrasting settings: the USA, which has a relatively low AMR burden, and Thailand, which has much higher consumption and drug resistance rates for antibiotics,” says Prof Philippe Guerin, co-author and Director of <span><u><a href="http://www.iddo.org">IDDO</a></u></span>.</span></span></span></p> <p><span><span><span>“Generating strong estimates of the costs associated with antimicrobial resistance is very difficult, but is a challenge that we must attempt to overcome if we are to make the best use of the resources available and fight drug resistance,” explains Prof Joanna Coast, researcher at the School of Social and Community Medicine, University of Bristol.</span></span></span></p> <p><span><span><span>Noting that their assumptions are conservative and likely underestimate the full economic costs of AMR per antibiotic consumed, the study authors suggest that further studies are urgently needed.</span></span></span></p> <p><span><span><span>“We have to start dealing with the AMR issue head on, and curbing the unnecessary use of antibiotics is key. We are keen to develop further studies across SE Asia, where we find the highest rates of AMR. Many SE Asian countries have little regulation of antibiotics and a big, informal medicine dispensing sector that aggravates the AMR problem. The study findings can help identify cost-effective interventions to fight AMR. Failing to act now puts the lives of millions at risk as treatment failures become increasingly widespread,” said Prof. Lubell. </span></span></span></p> <p> </p> <p><strong><span><span><span>Notes: </span></span></span></strong></p> <p><span><span><span><span><u><em><a href="https://aricjournal.biomedcentral.com/articles/10.1186/s13756-018-0384-3">Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use.</a></em></u></span><em> </em>Shrestha P, Cooper BS, Coast J, Oppong R, Do Thi Thuy NDT, Phodha T, Celhay O, Guerin PJ, Wertheim H, Lubell Y. <span><u><span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Enumerating+the+economic+cost+of+antimicrobial+resistance+per+antibiotic+consumed+to+inform+the+evaluation+of+interventions+affecting+their+use." title="Antimicrobial resistance and infection control."><span>Antimicrob Resist Infect Control.</span></a></span></u></span> <span>2018 Aug 9;7:98. doi: 10.1186/s13756-018-0384-3. eCollection 2018.</span></span></span></span></p> <p><span><span><span>Use this web-based application to calculate the economic cost of AMR for other countries: <span><u><a href="https://moru.shinyapps.io/amrcost/">https://moru.shinyapps.io/amrcost/</a></u></span> .</span></span></span></p> <p><span><span><span>This web-based application can be used to calculate the economic cost of AMR in different countries. The user can use the default values provided or choose to customise the input parameters (e.g. for a different country, given the availability of data) to generate a menu of costs of AMR.</span></span></span></p></div> </div> <div class="col-xs-12 col-sm-4 col-md-3"> </div> </div></div> <div class="col-sm-12 content-paragraphs"> </div> </div> Wed, 22 Aug 2018 15:16:10 +0000 bradley.smith 357 at https://www.iddo.org Applications Open for Global Health Journalism Fellowship https://www.iddo.org/news/applications-open-global-health-journalism-fellowship <div class="iddo-page-wrapper row full-width"> <div class="col-sm-12 full-width-gutter content-introduction-area"> <div class="row"> <div class="col-xs-12 col-sm-8 col-md-8"> <div class="field field--name-node-title field--type-ds field--label-hidden field--item"><h1> Applications Open for Global Health Journalism Fellowship </h1> </div> <div class="news-type-and-date"> <div class="field field--name-node-post-date field--type-ds field--label-hidden field--item">03 Aug 2018</div> </div> <div class="field field--name-field-introduction field--type-text-long field--label-hidden field--item"><p>The 2018 Global Health Journalism Fellowship will invite outstanding young journalists to participate in the first ever international conference on <a href="https://www.tropicalmedicine.ox.ac.uk/medicinequality2018/" rel="nofollow" target="_blank">Medicine Quality and Public Health</a> at the University of Oxford. Application deadline is 12 August 2018</p></div> </div> <div class="col-xs-12 col-sm-4 col-md-4"> <div class="field field--name-field-image field--type-image field--label-hidden field--item"> <img src="/sites/default/files/styles/standard_image_crop/public/news/journalism%20fellowship%201.jpg?itok=yyEJ-9In" width="600" height="400" alt="Credit: iStock" title="Credit: iStock" typeof="foaf:Image" class="img-responsive" /> </div> </div> </div> </div> <div class="col-sm-12 full-width-gutter content-bottom"><div class="row"> <div class="col-xs-12 col-sm-8 col-md-9"> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>The proliferation of poor quality medical products (medicines, vaccines and devices) is an important but neglected public health problem, threatening millions of lives in developing and developed countries. Accurate journalistic reporting is essential to ensure that the public are aware of the dangers of falsified and substandard medicines but are not discouraged from taking appropriate medicines and seeking medical advice. </p> <p>Therefore, the 2018 Global Health Journalism Fellowship will invite outstanding young journalists to participate in the first ever international conference on <a href="https://www.tropicalmedicine.ox.ac.uk/medicinequality2018/" rel="nofollow" target="_blank">Medicine Quality and Public Health</a> at the University of Oxford, from 23-28 September.</p> <p>This conference will bring together over 200 stakeholders from academia, NGOs, private sector organisations and policy-makers to discuss the opportunites to strengthen international collaboration in medicine quality and how to provide more high quality evidence. It will provide a unique opportunity for talented journalists to network with international experts and forge stronger connections between scientists, policy-makers and journalists.</p> <p>The deadline for applications is <strong>Sunday, 12 August 2018 at 23:59 (BST); </strong>the successful Fellowship applicants will be confirmed by late August 2018. <br />  </p> <h3><strong>Application process</strong></h3> <ul><li>Submission of 1 published piece of work with a focus on medicine quality issues or global health in any format (print, digital, audio or video), published since 1 January 2016.</li> <li>The article should be in English but translations will be accepted if the original article is also attached.</li> <li>An up-to-date CV</li> <li>A completed application form (enclosed below)</li> <li>A copy of your current passport photo page</li> </ul><p><em>Note: applications without one of these documents will not be considered</em></p> <p>Please submit your application (publication, CV, application form and current passport) to <a href="mailto:mqph2018%40ndm.ox.ac.uk">mqph2018@ndm.ox.ac.uk</a> with the title Global Health Journalism Fellowship application. </p> <p><strong>Selection criteria</strong></p> <ul><li>Applicants should be: <ul><li>Early career journalists with a maximum of 5 years of experience</li> <li>A national of a <a href="https://data.worldbank.org/income-level/low-and-middle-income" rel="nofollow" target="_blank">low- or middle-income country</a></li> <li>Able to demonstrate your interest in global health issues</li> <li>Able to demonstrate a commitment to balanced, accurate reporting through your submitted piece</li> <li>Available to attend the Conference between 23-28 September 2018 in Oxford, UK</li> </ul></li> </ul><p><em>Note: We strongly advise journalists to check with the relevant UK embassy about the visa application process in advance and confirm they can acquire a visa within four-weeks, if successful.</em> <br />  </p> <h3><strong>Benefits</strong></h3> <ul><li>Selected journalists will receive a bespoke briefing from communications experts and world-leading scientists at the Universit of Oxford</li> <li>The Conference provides a unique opportunity for networking with global health experts and other journalists interested in medicine quality and related issues</li> <li>Support for interview requests and access to speakers will be provided</li> <li>A certificate of participation will be provided after the Conference</li> <li>The fellowship will cover the costs for <ul><li>Flights from the country of residency to the UK</li> <li>A standard visitor visa for travel to the UK</li> <li>Registration for 5 days at the Medicine Quality and Public Health conference</li> <li>5 days accommodation and meals at the conference venue</li> </ul></li> </ul><p><br /><a href="https://www.tropicalmedicine.ox.ac.uk/medicinequality2018/journalism-fellowship/" rel="nofollow" target="_blank">Find out more about MQPH 2018</a> and download the application form <a href="https://www.tropicalmedicine.ox.ac.uk/medicinequality2018/journalism-fellowship/" rel="nofollow" target="_blank">here</a>.</p></div> </div> <div class="col-xs-12 col-sm-4 col-md-3"> </div> </div></div> <div class="col-sm-12 content-paragraphs"> <div class="field--comments"> <div class="row"> <div class="col-lg-12"> <section> <h2>Add new comment</h2> <drupal-render-placeholder callback="comment.lazy_builders:renderForm" arguments="0=node&amp;1=316&amp;2=field_comments&amp;3=comment" token="yBXVFoPMLdsS_MHlV-h8R9TiaXpcWZ17swP4aBfmoVs"></drupal-render-placeholder> </section> </div> </div> </div> </div> </div> Fri, 03 Aug 2018 09:24:54 +0000 bradley.smith 316 at https://www.iddo.org Experts to seek consensus on tackling poor quality medicines https://www.iddo.org/news/experts-seek-consensus-tackling-poor-quality-medicines <div class="iddo-page-wrapper row full-width"> <div class="col-sm-12 full-width-gutter content-introduction-area"> <div class="row"> <div class="col-xs-12 col-sm-8 col-md-8"> <div class="field field--name-node-title field--type-ds field--label-hidden field--item"><h1> Experts to seek consensus on tackling poor quality medicines </h1> </div> <div class="news-type-and-date"> <div class="field field--name-node-post-date field--type-ds field--label-hidden field--item">31 May 2018</div> </div> <div class="field field--name-field-introduction field--type-text-long field--label-hidden field--item"><p>A pioneering conference will bring leading professionals from all over the world to Oxford, UK to discuss strategies for tackling poor quality medical products on a global scale.</p></div> </div> <div class="col-xs-12 col-sm-4 col-md-4"> <div class="field field--name-field-image field--type-image field--label-hidden field--item"> <img src="/sites/default/files/styles/standard_image_crop/public/news/World%20Map.png?itok=bTx552GN" width="600" height="300" alt="Credit: United States Pharmacopeial Convention (USP)" title="Credit: United States Pharmacopeial Convention (USP)" typeof="foaf:Image" class="img-responsive" /> </div> </div> </div> </div> <div class="col-sm-12 full-width-gutter content-bottom"><div class="row"> <div class="col-xs-12 col-sm-8 col-md-9"> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>The proliferation of poor quality medical products (medicines, vaccines and devices) is an important but neglected public health problem, threatening millions of people all over the world, both in developing and wealthy countries. A recent report from the World Health Organization found that an estimated <a href="https://www.iddo.org/news/news-articles/WHO-medical-products-publications" rel="nofollow" target="_self">1 in 10 medicines</a> in low- and middle-income countries were falsified or substandard. Falsified diazepam found across Scotland has been reported as being “cheaper than chips”.</p> <p>Falsified and substandard medicines, which may have the incorrect or wrong dose of pharmaceutical ingredients, or no active ingredients at all, may result in death, prolonged illness, side effects or loss of trust in healthcare systems; for antimicrobials they are also likely to be a key driver of antimicrobial resistance (AMR).</p> <p>“Our ability to tackle the issue is hampered by its complexity,” said Prof Paul Newton, Head of the <a href="https://www.iddo.org/medicine-quality" rel="nofollow" target="_self">Medicine Quality Group at the Infectious Diseases Data Observatory (IDDO) </a>and the instigator of the conference. “Criminals are becoming more sophisticated, using the internet as well as offline pharmacies for distribution, creating falsified medicines and working across geographical boundaries and in countries with varying legislation and levels of enforcement. Errors in factories without sufficient quality control results in substandard medicines, often containing insufficient ingredients, that because they look genuine are hard to detect.</p> <p>“The issue affects a broad range of stakeholders from individual patients, pharmacists and medicine regulatory authorities to the pharmaceutical industry and law enforcement agencies. We need to better understand the scale of the problem, raise awareness and encourage interventions and support so that every country has a functional medicine regulatory agency to ensure that we all have access to medicines we can trust ,” said Prof Newton.</p> <p>“The conference will be an important opportunity for the diverse stakeholders involved in medicine quality and regulation to come together within the framework of a dedicated academic conference to share ideas and expertise. One of the event’s key objectives is to develop a consensus statement to be widely disseminated to interested parties and policy-makers, forming the basis of a coordinated global effort to tackle poor quality medical products.”</p> <p>The <a href="http://www.tropicalmedicine.ox.ac.uk/medicinequality2018/" rel="nofollow" target="_blank">Medicine Quality &amp; Public Health Conference</a> (MQPH2018) will provide a unique opportunity for medicines regulatory authorities, health workers, scientists, pharmacists, sociologists, economists and international organisations to discuss the problem and outline the necessary steps to address this important issue.</p> <p>The Conference is expected to attract leading authorities from all over the world, including representatives from a diversity of organisations in low- and middle-income countries, where the issue of poor quality medicines is often more pronounced due to inadequate surveillance systems.</p> <p>More information about the speakers can be found on the conference <a href="https://www.tropicalmedicine.ox.ac.uk/medicinequality2018/speakers-2/" rel="nofollow" target="_blank">website</a>.</p> <p>The Medicine Quality &amp; Public Health Conference will take place at Keble College, Oxford from 23-28 September 2018. If you are interested in attending the conference or would like to find out more, please visit the conference <a href="http://www.tropicalmedicine.ox.ac.uk/medicinequality2018/about/" rel="nofollow" target="_blank">website</a> or email <a href="mailto:mqph2018%40ndm.ox.ac.uk">mqph2018@ndm.ox.ac.uk</a>. </p> <p>Join our discussion on Twitter #MQPH2018 </p> <p>The deadline for submitting abstracts is <strong>18 June 2018.</strong></p> <p>The deadline for registration is <strong>31 August 2018.</strong></p> <p>A limited number of <strong>early bird places</strong> are available on a first come, first served basis.</p> <p> </p> <p><strong>Editor’s notes</strong><strong> </strong></p> <p><a href="https://www.tropicalmedicine.ox.ac.uk/medicinequality2018/" rel="nofollow" target="_blank"><strong>The Medicine Quality &amp; Public Health Conference</strong></a> is being organised by the Centre for Tropical Medicine &amp; Global Health at the University of Oxford, the Infectious Diseases Data Observatory and the <a href="http://www.tropmedres.ac/home" rel="nofollow" target="_blank">Mahidol Oxford Tropical Medicine Research Unit</a>. </p> <p><a href="https://www.iddo.org/medicine-quality" rel="nofollow"><strong>IDDO’s Medicine Quality Group</strong></a> encourages discussion of poor quality medicine epidemiology, detection and prevention, and aims to facilitate improvement in the quality of medicines that patients take. IDDO facilitates the sharing of data and expertise and collation of information to increase understanding of the prevalence and distribution of poor quality medicines around the world. </p> <p><a href="https://www.iddo.org/news/news-articles/new-terminology" rel="nofollow" target="_self">Definitions of<strong> falsified and substandard medicines </strong></a>were agreed by the World Health Organization in May 2017. The definitions are: “Substandard” medical products (also called “out of specification”) are authorized by national regulatory authorities, but fail to meet either national or international quality standards or specifications – or in some cases, both. “Falsified” medical products deliberately or fraudulently misrepresent their identity, composition or source. </p> <p>For further information or interviews, please contact Jing Xu <a href="mailto:jing.xu%40iddo.org">jing.xu@iddo.org</a> or Anne Whitehouse <a href="mailto:anne.whitehouse%40iddo.org">anne.whitehouse@iddo.org</a> +44(0) 1865 612948.</p></div> </div> <div class="col-xs-12 col-sm-4 col-md-3"> </div> </div></div> <div class="col-sm-12 content-paragraphs"> </div> </div> Thu, 31 May 2018 16:01:11 +0000 bradley.smith 272 at https://www.iddo.org Study analyses AMR networks in low- and middle-income countries https://www.iddo.org/news/study-analyses-amr-networks-low-and-middle-income-countries <div class="iddo-page-wrapper row full-width"> <div class="col-sm-12 full-width-gutter content-introduction-area"> <div class="row"> <div class="col-xs-12 col-sm-8 col-md-8"> <div class="field field--name-node-title field--type-ds field--label-hidden field--item"><h1> Study analyses AMR networks in low- and middle-income countries </h1> </div> <div class="news-type-and-date"> <div class="field field--name-node-post-date field--type-ds field--label-hidden field--item">05 Mar 2018</div> </div> <div class="field field--name-field-introduction field--type-text-long field--label-hidden field--item"><p>A new study published today reveals the challenges of establishing sustainable and effective networks to tackle resistance to antimicrobial medicines in low- and middle-income countries (LMICs).</p></div> </div> <div class="col-xs-12 col-sm-4 col-md-4"> <div class="field field--name-field-image field--type-image field--label-hidden field--item"> <img src="/sites/default/files/styles/standard_image_crop/public/news/Credit%20IDDO%20Mehul%20Dhorda.jpg?h=54380a9a&amp;itok=FQby5CtJ" width="480" height="300" alt="IDDO/ Mehul Dhorda" title="Credit: IDDO/ Mehul Dhorda" typeof="foaf:Image" class="img-responsive" /> </div> </div> </div> </div> <div class="col-sm-12 full-width-gutter content-bottom"><div class="row"> <div class="col-xs-12 col-sm-8 col-md-9"> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>The study, ‘<a href="https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dky026/4921008" rel="nofollow" target="_blank" title="Journal of Antimicrobial Chemotherapy">An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000</a>’, points out that strong leadership and sustained investment are essential to overcome the challenges.</p> <p>LMICs shoulder the bulk of the global burden of infectious diseases and drug resistance, and whilst awareness of the threat of antimicrobial resistance (AMR) is growing, LMICs often have weaker surveillance systems and fewer resources to tackle the problem. </p> <p>The study provides an analysis of supranational AMR surveillance networks involving LMICs that were in existence between January 2000 and August 2017. It assesses the impact and challenges of these networks and the implications for the <a href="http://www.who.int/glass/en/" rel="nofollow" target="_blank" title="Global Antimicrobial Resistance Surveillance System">Global Antimicrobial Resistance Surveillance System (GLASS)</a>. 72 AMR supranational networks were identified, but over half of them have already collapsed due to a variety of challenges, including the inability to secure ongoing funding.</p> <p>An effective surveillance system is the cornerstone of assessing the burden of AMR and for providing the necessary information for action. The biggest challenges faced by the global networks were achieving high coverage across LMICs and complying with the recommended frequency of reporting.</p> <p>In 2015, the 68th World Health Assembly adopted a <a href="http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/" rel="nofollow" target="_blank">Global Action Plan on Antimicrobial Resistance</a> and the <a href="http://www.who.int/glass/en/" rel="nofollow" target="_blank" title="Global Antimicrobial Resistance Surveillance System">GLASS</a> was established to support the implementation of one of the Plan’s five strategic objectives - to strengthen the evidence base through enhanced global surveillance and research.</p> <p>GLASS aims to build up passive surveillance of antibacterial resistance integrated into routine case-management of patients, replacing the current monitoring methods for HIV, TB and malaria drug resistance, which usually rely on active surveillance efforts such as cross-sectional surveys or observational studies at sentinel sites.</p> <p>However, lack of resources, low coverage and un-standardised surveillance activities in LMICs could challenge this global initiative. “Our analysis suggests that complementary active approaches may be needed in many LMICs. Antimicrobial resistance surveillance requires a level of laboratory infrastructure and training which is not always available,” said Dr Elizabeth Ashley, lead author of the study and Clinical Researcher at the <a href="http://www.tropmedres.ac/mocru-myanmar" rel="nofollow" target="_blank">Myanmar-Oxford Clinical Research Unit</a>, University of Oxford.</p> <p>The study suggests that a successful AMR surveillance network should be able to generate up-to-date comparable, representative, high-quality data. However, the networks identified were initiated by a variety of different organisations, including the World Health Organization, the pharmaceutical industry, and academic groups, resulting in a diversity of approaches. For example, academic networks tend to focus AMR surveillance around one specific clinical question while pharmaceutical companies had the objective of evaluating susceptibility to one specific drug.</p> <p>Despite the challenges, Dr Ashley remains optimistic: “Having a better understanding of the challenges is the first step towards solving them. It is a positive sign that the UK government along with international organisations have vowed to tackle this issue and made a significant investment in supporting efforts to understand and address AMR.”</p> <p>Ashley et al suggest that successful networks need strong leadership and coordination, and should influence policy and guidelines to have a positive impact on human and animal health. A ‘<a href="http://www.who.int/features/qa/one-health/en/" rel="nofollow" target="_blank">One Health</a>’ approach to surveillance would take into account the interaction between drivers of AMR in humans, animals and the environment, and an up-to-date registry of networks could support a more coordinated approach, reduce duplication of effort, and improve sustainability.</p> <p><strong>Publication details</strong><br /> Elizabeth A Ashley, Judith Recht, Arlene Chua, David Dance, Mehul Dhorda, Nigel V Thomas, Nisha Ranganathan, Paul Turner, Philippe J Guerin, Nicholas J White, Nicholas P Day; An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000, <em>Journal of Antimicrobial Chemotherapy</em>, dky026, <a href="https://doi.org/10.1093/jac/dky026" rel="nofollow" target="_blank">https://doi.org/10.1093/jac/dky026</a>. PMID: 29514279</p> <p>This publication is the result of an independent study commissioned by Wellcome and funded by the UK’s Department of Health.</p></div> </div> <div class="col-xs-12 col-sm-4 col-md-3"> </div> </div></div> <div class="col-sm-12 content-paragraphs"> </div> </div> Mon, 05 Mar 2018 00:00:00 +0000 bradley.smith 187 at https://www.iddo.org Oxford University to host 2018 Quality of Medical Products and Public Health short course https://www.iddo.org/news/oxford-university-host-2018-quality-medical-products-and-public-health-short-course <div class="iddo-page-wrapper row full-width"> <div class="col-sm-12 full-width-gutter content-introduction-area"> <div class="row"> <div class="col-xs-12 col-sm-8 col-md-8"> <div class="field field--name-node-title field--type-ds field--label-hidden field--item"><h1> Oxford University to host 2018 Quality of Medical Products and Public Health short course </h1> </div> <div class="news-type-and-date"> <div class="field field--name-node-post-date field--type-ds field--label-hidden field--item">23 Feb 2018</div> </div> <div class="field field--name-field-introduction field--type-text-long field--label-hidden field--item"><p>The fourth <a href="https://www.conted.ox.ac.uk/courses/quality-of-medical-products-and-public-health?code=O19C027B9Y" rel="nofollow" target="_blank">Quality of Medical Products and Public Health course</a> will take place in Oxford this year, from 17-21 September, at Wolfson College. This multidisciplinary course is aimed at professionals who are interested in the quality of medical products. The application deadline is 18 May.</p></div> </div> <div class="col-xs-12 col-sm-4 col-md-4"> <div class="field field--name-field-image field--type-image field--label-hidden field--item"> <img src="/sites/default/files/styles/standard_image_crop/public/news/Credit%20Boston%20University%20School%20of%20Public%20Health%20Population%20Health%20Exchange.jpg?h=eb9c1e9d&amp;itok=2Tbt3vzX" width="480" height="300" alt="Boston University School of Public Health/ Population Health Exchange" title="Credit: Boston University School of Public Health/ Population Health Exchange" typeof="foaf:Image" class="img-responsive" /> </div> </div> </div> </div> <div class="col-sm-12 full-width-gutter content-bottom"><div class="row"> <div class="col-xs-12 col-sm-8 col-md-9"> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>The World Health Organization (WHO) estimated that <a href="https://www.iddo.org/news/news-articles/WHO-medical-products-publications" rel="nofollow">one in ten</a> medical products in developing countries are substandard or falsified, and modelling by the London School of Hygiene &amp; Tropical Medicine estimates that around 116,000 additional deaths from malaria could be caused every year by substandard and falsified antimalarials in sub-Saharan Africa*.The lack of capacity in quality assurance of medical products, especially in low- or middle-income countries (LMICs) is one of the key challenges.</p> <p>To address the need to increase capacity and stimulate more research and action on medicine quality, the London School of Hygiene &amp; Tropical Medicine (LSHTM) and the University of Oxford started the short course on the Quality of Medical Products and Public Health in 2015.</p> <p>To date, it has brought together professionals from more than 27 countries, who work in regulatory bodies, health policy and funding agencies, international health organizations, academia, and pharmaceutical industries, to discuss key medicine quality problems. “Seeing people discuss the issue and often come to a consensus on what needs to be done has been wonderful,” said Prof Paul Newton, course director and head of the IDDO Medicine Quality Group. </p> <p>This year, <a href="https://www.conted.ox.ac.uk/courses/quality-of-medical-products-and-public-health" rel="nofollow" target="_blank">the course</a> will be hosted by the <a href="https://www.ndm.ox.ac.uk/home" rel="nofollow" target="_blank">Nuffield Department of Medicine, University of Oxford</a>, and the instructors will be drawn from a range of regulatory agencies, international organisations, universities and generic and innovator pharmaceutical companies. We expect speakers from diverse bodies including the Infectious Diseases Data Observatory, Institute of Tropical Medicine, Belgium, LSHTM, United States Pharmacopeial Convention, and the WHO. </p> <p>The programme will include: medicine quality definitions, the epidemiology of poor quality medicines and the data gaps that need to be filled; the basics of medicine regulation, good manufacturing practice and laws relating to medicine quality; the basics of chemical and packaging analysis and rapid tests; and the steps needed to improve the global supply of quality assured medicines, and how to advocate for them.  </p> <p>The previous three courses have been hosted by LSHTM in 2016 and 2015 then by <a href="https://www.iddo.org/news/news-articles/boston-university-host-2017-quality-medical-products-and-public-health-short" rel="nofollow">Boston University School of Public Health in 2017</a>.</p> <p>‘It was very good to have an introduction and overview of where we actually stand in the field of research and knowledge. I learnt about a few ongoing or very recent studies that I had not been aware of,” said Prof Lutz Heide, Professor of Pharmaceutical Biology at the University of Tübingen who attend the course in 2016.</p> <p> “I took this course because I want to share and I want to hear from other countries what they do and what their strategies are,” said Tanti Yulianti, a former attendee and Pharmaceutical Analyst at the National Quality Control Laboratory of Drug &amp; Food in Indonesia. “Maybe we can find a better one for our country.” </p> <p>“I've learnt much more about the topic of internet pharmacies and the level of technology that they are using to mask their origin and stay online, despite efforts to close them down,” said Professor Facundo Fernandez, Georgia Institute of Technology, who taught on the course in 2016. “I learnt a lot of things that I had no idea of before.” </p> <p>The registration fee for the course is £1,600.00, including the accommodation and most meals. Full bursaries are also available. <strong>The deadline to apply for a place is 18 May.</strong></p> <p>The first international academic conference on Medicine Quality &amp; Public Health will also take place in Oxford, UK, the week after the course, allowing participants to easily attend both events. More information can be found <a href="http://www.tropicalmedicine.ox.ac.uk/medicinequality2018/" target="_blank">here</a>.</p> <p>* <a href="http://who.int/medicines/regulation/ssffc/publications/SummarySESTUDY-WEB.pdf" rel="nofollow" target="_blank">A study on the public health and socioeconomic impact of substandard and falsified medical products: executive summary</a>: Geneva: World Health Organization; 2017 (WHO/EMP/RHT/SAV/2017.02). Licence: CC BY-NC-SA 3.0 IGO. </p></div> </div> <div class="col-xs-12 col-sm-4 col-md-3"> </div> </div></div> <div class="col-sm-12 content-paragraphs"> </div> </div> Fri, 23 Feb 2018 00:00:00 +0000 bradley.smith 186 at https://www.iddo.org 1 in 10 medical products in developing countries is substandard or falsified https://www.iddo.org/news/1-10-medical-products-developing-countries-substandard-or-falsified <div class="iddo-page-wrapper row full-width"> <div class="col-sm-12 full-width-gutter content-introduction-area"> <div class="row"> <div class="col-xs-12 col-sm-8 col-md-8"> <div class="field field--name-node-title field--type-ds field--label-hidden field--item"><h1> 1 in 10 medical products in developing countries is substandard or falsified </h1> </div> <div class="news-type-and-date"> <div class="field field--name-node-post-date field--type-ds field--label-hidden field--item">29 Nov 2017</div> </div> <div class="field field--name-field-introduction field--type-text-long field--label-hidden field--item"><p>Two new WHO publications highlight the prevalence and impact of substandard and falsified medical products. An estimated 1 in 10 medical products circulating in low- and middle-income countries is either substandard or falsified, according to new research from the World Health Organization (WHO).</p></div> </div> <div class="col-xs-12 col-sm-4 col-md-4"> <div class="field field--name-field-image field--type-image field--label-hidden field--item"> <img src="/sites/default/files/styles/standard_image_crop/public/news/Pills.jpg?h=998b4263&amp;itok=OktmURDi" width="480" height="300" alt="An estimated 1 in 10 medical products circulating in low- and middle-income countries is either substandard or falsified" typeof="foaf:Image" class="img-responsive" /> </div> </div> </div> </div> <div class="col-sm-12 full-width-gutter content-bottom"><div class="row"> <div class="col-xs-12 col-sm-8 col-md-9"> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>This means that people are taking medicines that fail to treat or prevent disease. Not only is this a waste of money for individuals and health systems that purchase these products, but substandard or falsified medical products can cause serious illness or even death. </p> <p>“Substandard and falsified medicines particularly affect the most vulnerable communities,” says Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Imagine a mother who gives up food or other basic needs to pay for her child’s treatment, unaware that the medicines are substandard or falsified, and then that treatment causes her child to die. This is unacceptable. Countries have agreed on measures at the global level – it is time to translate them into tangible action.”</p> <p>WHO launched its Global Surveillance and Monitoring System for substandard and falsified medicines, vaccines and in-vitro diagnostic tests in July 2013. <a href="http://who.int/medicines/regulation/ssffc/publications/gsms-report-sf/en/" rel="nofollow" target="_blank" title="WHO medicine quality report">The report</a>, published today, is based on data collected during the first four years of operation up to 30 June 2017.</p> <p>The second publication is ‘<a href="http://who.int/medicines/regulation/ssffc/publications/se-study-sf/en/" rel="nofollow" target="_blank" title="WHO medicine quality report">A study on the public health and socioeconomic impact of substandard or falsified medical products</a>’ conducted by WHO and the Member State Mechanism. This study, based on 100 literature reviews and two peer-reviewed models developed by the University of Edinburgh and the London School of Hygiene &amp; Tropical Medicine, estimates a 10.5% failure rate in all medical products used in low- and middle-income countries. The 100 papers reviewed provide data for more than 48,000 samples of medicines from 88 countries.</p> <p>Together, the two reports represent the most comprehensive compilation to date of data related to substandard and falsified medical products and are a first step towards better understanding their public health and socioeconomic impact.</p> <p>Since 2013, WHO has received 1500 reports of cases of substandard or falsified products. Of these, antimalarials and antibiotics are the most commonly reported. Most of the reports (42%) come from the WHO African Region, 21% from the WHO Region of the Americas, and 21% from the WHO European Region. </p> <p>It is thought that this is just a small fraction of the total problem and many cases may be going unreported. For example, only 8% of reports of substandard or falsified products to WHO came from the WHO Western Pacific Region, 6% from the WHO Eastern Mediterranean Region, and just 2% from the WHO South-East Asia Region.</p> <p>“Many of these products, like antibiotics, are vital for people’s survival and wellbeing,” says Dr Mariângela Simão, Assistant Director-General for Access to Medicines, Vaccines and Pharmaceuticals at WHO. “Substandard or falsified medicines not only have a tragic impact on individual patients and their families, but also are a threat to antimicrobial resistance, adding to the worrying trend of medicines losing their power to treat.”</p> <p><strong>The two reports are available on the WHO website:</strong></p> <ul><li><a href="http://who.int/medicines/regulation/ssffc/publications/gsms-report-sf/en/" rel="nofollow" target="_blank">WHO Global Surveillance and Monitoring System for substandard and falsified medical products</a></li> <li><a href="http://who.int/medicines/regulation/ssffc/publications/se-study-sf/en/" rel="nofollow" target="_blank">A study on the public health and socioeconomic impact of substandard and falsified medical products</a></li> </ul><p>You can also watch the launch of the publications on <a href="https://www.youtube.com/watch?v=DxygsHyag14" rel="nofollow" target="_blank" title="Medicine quality publications launch">YouTube</a></p> <p>Information courtesy of <a href="http://who.int/mediacentre/news/releases/2017/substandard-falsified-products/en/" rel="nofollow" target="_blank" title="WHO Media Centre">WHO Media centre</a>. </p></div> </div> <div class="col-xs-12 col-sm-4 col-md-3"> </div> </div></div> <div class="col-sm-12 content-paragraphs"> </div> </div> Wed, 29 Nov 2017 00:00:00 +0000 bradley.smith 185 at https://www.iddo.org New review highlights need for soil-transmitted helminths data sharing platform https://www.iddo.org/news/new-review-highlights-need-soil-transmitted-helminths-data-sharing-platform <div class="iddo-page-wrapper row full-width"> <div class="col-sm-12 full-width-gutter content-introduction-area"> <div class="row"> <div class="col-xs-12 col-sm-8 col-md-8"> <div class="field field--name-node-title field--type-ds field--label-hidden field--item"><h1> New review highlights need for soil-transmitted helminths data sharing platform </h1> </div> <div class="news-type-and-date"> <div class="field field--name-node-post-date field--type-ds field--label-hidden field--item">07 Nov 2017</div> </div> <div class="field field--name-field-introduction field--type-text-long field--label-hidden field--item"><p>New<a href="https://doi.org/10.1371/journal.pntd.0006053" rel="nofollow" target="_blank"> literature review</a> on soil-transmitted helminths provides compelling evidence for the need to develop a data sharing platform to monitor and improve treatment outcomes for this neglected tropical disease.</p></div> </div> <div class="col-xs-12 col-sm-4 col-md-4"> <div class="field field--name-field-image field--type-image field--label-hidden field--item"> <img src="/sites/default/files/styles/standard_image_crop/public/news/19293_lores.jpg?itok=6d6gYZ0q" width="600" height="399" alt="Man using microscope in field study" title="Credit: Alaine Kathryn Knipes; Parasitic Disease Branch (DPDx); Division of Parasitic Diseases and Malaria" typeof="foaf:Image" class="img-responsive" /> </div> </div> </div> </div> <div class="col-sm-12 full-width-gutter content-bottom"><div class="row"> <div class="col-xs-12 col-sm-8 col-md-9"> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>Soil-transmitted helminths (STHs) are estimated to affect over one billion people. The most prevalent infections - hook worm, whip worm and round worm - primarily affect the poorest populations in lower and middle income countries and are responsible for exerting a great health and economic toll on the regions worst affected.</p> <p>STHs are normally treated using two drugs, albendazole and mebendazole. These are both routinely given to children as part of mass drug administration projects such as preventative chemotherapy and transmission control. Although these programmes have been scaled-up significantly over the past few years, very little evaluation or monitoring of drug efficacy takes place to understand how well these treatments are performing.</p> <p>This study published in <a href="https://doi.org/10.1371/journal.pntd.0006053" rel="nofollow" target="_blank">PLOS Neglected Tropical Diseases</a> systematically reviewed all studiess published since 2000 to understand the variation in the design, implementation and evaluation of the programmes and projects. They study also reviews the abundance of individual participant data that could be potentially in meta-analyses. The study explored data from 35,000 patients who took part in 129 studies across 39 studies.</p> <p>The findings of this review suggest that that there is sufficient data to justify a dedicated STH data platform. Creating such a resource for STH could assist clinicians, drug developers and health care policy makers to guide treatment options today and help design better therapies and disease control strategies in the future.</p> <p>Population of a database with individual participant data from clinical trials would enable the global health community to monitor effectively drug efficacy, to respond accordingly to the changes, and thereby to safeguard the effectiveness of STH control.</p> <p><strong>Publication details:</strong></p> <p>Halder JB, Benton J, Julé AM, Guérin PJ, Olliaro PL, Basáñez M-G, et al. (2017) Systematic review of studies generating individual participant data on the efficacy of drugs for treating soil-transmitted helminthiases and the case for data-sharing. PLoS Negl Trop Dis11(10): e0006053. <a href="https://doi.org/10.1371/journal.pntd.0006053" rel="nofollow" target="_blank">https://doi.org/10.1371/journal.pntd.0006053</a></p></div> </div> <div class="col-xs-12 col-sm-4 col-md-3"> <div class="field field--name-field-featured-content field--type-entity-reference field--label-hidden field--items"> <div class="field--item"> <div data-history-node-id="148" class="layout layout--onecol"> <div class="layout__region layout__region--content"> <div class="field field--name-field-image field--type-image field--label-hidden field--item"> <div class="image-with-caption"> <img src="/sites/default/files/styles/featured_view_item/public/news/Copyright%20%20Anita%20KhemkaDNDi-website.jpg?h=978032de&amp;itok=35GifKNF" width="600" height="369" alt="Credit: Anita Khemka / DNDi" title="Credit: Anita Khemka / DNDi" typeof="foaf:Image" class="img-responsive" /> <div class="image-caption-wrapper"> <div class="caption-toggle">i</div> <div class="caption">Credit: Anita Khemka / DNDi</div> </div> </div> </div> <div class="news-type-and-date"> <div class="field field--name-field-news-type field--type-entity-reference field--label-hidden field--item">News Article</div> <div class="field field--name-node-post-date field--type-ds field--label-hidden field--item">07 Sep 2017</div> </div> <div class="field field--name-node-title field--type-ds field--label-hidden field--item"><div> Pooling patient data could improve VL treatment options </div> </div> </div> </div> </div> </div> </div> </div></div> <div class="col-sm-12 content-paragraphs"> </div> </div> Tue, 07 Nov 2017 00:00:00 +0000 aileen.sheehy 154 at https://www.iddo.org We’re at ASTMH 2017 – come and meet the team! https://www.iddo.org/news/were-astmh-2017-come-and-meet-team <div class="iddo-page-wrapper row full-width"> <div class="col-sm-12 full-width-gutter content-introduction-area"> <div class="row"> <div class="col-xs-12 col-sm-8 col-md-8"> <div class="field field--name-node-title field--type-ds field--label-hidden field--item"><h1> We’re at ASTMH 2017 – come and meet the team! </h1> </div> <div class="news-type-and-date"> <div class="field field--name-node-post-date field--type-ds field--label-hidden field--item">01 Nov 2017</div> </div> <div class="field field--name-field-introduction field--type-text-long field--label-hidden field--item"><p>The IDDO team will be attending this year’s American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting held in Baltimore, USA. Visit the Centre for Tropical Medicine &amp; Global Health booth (number 312) in the exhibition area to meet staff members.</p></div> </div> <div class="col-xs-12 col-sm-4 col-md-4"> <div class="field field--name-field-image field--type-image field--label-hidden field--item"> <img src="/sites/default/files/styles/standard_image_crop/public/news/ASTMH.jpg?h=644ba163&amp;itok=TwjNQf1h" width="580" height="363" alt="ASTMH logo" title="Credit: ASTMH" typeof="foaf:Image" class="img-responsive" /> </div> </div> </div> </div> <div class="col-sm-12 full-width-gutter content-bottom"><div class="row"> <div class="col-xs-12 col-sm-8 col-md-9"> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>IDDO team members will participate in a variety of sessions and symposia. These take place alongside other <a href="http://www.wwarn.org/news/news-articles/meet-team-seasons-conferences" rel="nofollow" target="_blank">oral and poster presentations</a> that come under the WWARN malaria research.</p> <p>In Scientific Session 41,  IDDO Director Prof Philippe Guérin will discuss the latest partnership between IDDO and the Drugs for Neglected Diseases<em> Initiative</em> (DND<em>i</em>) in planning and delivering a visceral leishmaniasis (VL) data platform. This platform will maximise the utility of existing resources and enable researchers to address priority questions in VL treatment within a framework that recognises the contributions of data contributors and clinical trial participants.</p> <p> </p> <h2><strong>Monday 6 November, 3:15 - 3:30 PM</strong> </h2> <p>Session 41 - Kinetoplastida: Diagnosis, Treatment and Vaccine Development</p> <p>Convention Center - Room 337/338 (Level 300)</p> <ul type="disc"><li><a href="http://www.abstractsonline.com/pp8/#!/4395/presentation/1579" rel="nofollow" target="_blank"><strong>Maximizing the utility of VL clinical trial data within an ethical data-sharing framework</strong></a><strong> - Philippe Guérin</strong></li> </ul><p>A symposium on substandard and falsified medicines will be co-chaired by IDDO’s Head of Medicine Quality, Prof Paul Newton. This symposium will highlight some of the global initiatives underway related to the development and evaluation of existing and emerging screening technologies and discuss the future of these valuable and constantly evolving tools. IDDO’s Medicine Quality Scientific Coordinator, Dr Céline Caillet will present her own research into device use in pharmacy settings.</p> <p> </p> <h2><strong>Thursday 9 November 9, 8:00 - 9:45 AM</strong> </h2> <p>Session 181 - Lasers, Rays and Dyes: Tools and Initiatives in the Fight against Substandard and Falsified Medicines</p> <p>Convention Center - Room 327/328/329 (Level 300)</p> <p><strong>Co-Chair: Paul Newton</strong></p> <ul><li><a href="http://www.abstractsonline.com/pp8/#!/4395/presentation/556" rel="nofollow" target="_blank"><strong>How to find bad apples in pharmacies</strong></a><strong> - Céline Caillet</strong></li> </ul><p>We will also have a meeting room, so please contact us to arrange a side meeting during the conference. The meeting room is located in the Hilton - Tubman AB (West Building, Third Floor) - located across the street and connected by walkway to the Baltimore Convention Center.</p></div> </div> <div class="col-xs-12 col-sm-4 col-md-3"> <div class="field field--name-field-featured-content field--type-entity-reference field--label-hidden field--items"> <div class="field--item"> <div data-history-node-id="150" class="layout layout--onecol"> <div class="layout__region layout__region--content"> <div class="field field--name-field-image field--type-image field--label-hidden field--item"> <img src="/sites/default/files/styles/featured_view_item/public/news/iStock_000075193361_72dpi.jpg?h=2cac3301&amp;itok=z9uzaNk0" width="600" height="369" alt="Pill in hand" title="Credit: iStock" typeof="foaf:Image" class="img-responsive" /> </div> <div class="news-type-and-date"> <div class="field field--name-field-news-type field--type-entity-reference field--label-hidden field--item">News Article</div> <div class="field field--name-node-post-date field--type-ds field--label-hidden field--item">12 Oct 2017</div> </div> <div class="field field--name-node-title field--type-ds field--label-hidden field--item"><div> Poor quality medicines on the programme at ECTMIH, Belgium </div> </div> </div> </div> </div> </div> </div> </div></div> <div class="col-sm-12 content-paragraphs"> </div> </div> Wed, 01 Nov 2017 14:24:37 +0000 aileen.sheehy 153 at https://www.iddo.org